A major challenge facing Bosman these days has been trying to protect her pharmaceutical clients from being tarred with the same brush when a particular drug is called into question.
In the past year, her practice has focused on mass tort phamaceutical litigation and dealing with issues of product identification.
"Most of the cases involve hundreds of different individual claims, sometimes thousands, either in individual courts or coordinated ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In